BURNING ROCK BIOTECH LTD-ADR (BNR) Stock Price, Quote, News and Overview
NASDAQ:BNR - Nasdaq - US12233L2060 - ADR - Currency: USD
BNR Quote, Performance and Key Statistics
NASDAQ:BNR (2/21/2025, 8:03:58 PM)
7.15
+0.06 (+0.85%)
The current stock price of BNR is 7.15 USD. In the past month the price increased by 4.84%. In the past year, price decreased by -11.73%.
BNR Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About BNR
Company Profile
Burning Rock Biotech Ltd is a CN-based company operating in Biotechnology industry. The company is headquartered in Guangzhou, Guangdong and currently employs 786 full-time employees. The company went IPO on 2020-06-12. Burning Rock Biotech Ltd is a holding company mainly engaged in the next generation sequencing (NGS) based cancer therapy selection. The firm operates three segments. Central Laboratory Business segment is engaged in the sales of cancer therapy selection test to individual patients. In-Hospital Business segment is engaged in the sales of reagent kits and the provision of the facilitation services for the sale of laboratory equipment to hospitals. Pharma Research and Development Services segment provide services to companies primarily in relation to the development of targeted therapies and immunotherapies for various types of cancer, and to hospitals for their studies on cancer diagnosis and treatment. Its products include OncoScreen Plus and LungPlasma. Its NGS-based cancer therapy selection tests applicable to a broad range of cancer types, including lung cancer, prostate cancer, breast cancer and others. The firm mainly conducts its businesses in the China market.
Company Info
BURNING ROCK BIOTECH LTD-ADR
No. 5 Xingdao Ring Road North, International Bio Island
Guangzhou GUANGDONG 510005 CN
CEO: Yusheng Han
Employees: 786
Company Website: https://www.brbiotech.com/
Investor Relations: https://ir.brbiotech.com/
Phone: 8618501641666
BURNING ROCK BIOTECH LTD-ADR / BNR FAQ
What is the stock price of BURNING ROCK BIOTECH LTD-ADR today?
The current stock price of BNR is 7.15 USD. The price increased by 0.85% in the last trading session.
What is the ticker symbol for BURNING ROCK BIOTECH LTD-ADR stock?
The exchange symbol of BURNING ROCK BIOTECH LTD-ADR is BNR and it is listed on the Nasdaq exchange.
On which exchange is BNR stock listed?
BNR stock is listed on the Nasdaq exchange.
What is BURNING ROCK BIOTECH LTD-ADR worth?
BURNING ROCK BIOTECH LTD-ADR (BNR) has a market capitalization of 73.35M USD. This makes BNR a Micro Cap stock.
How many employees does BURNING ROCK BIOTECH LTD-ADR have?
BURNING ROCK BIOTECH LTD-ADR (BNR) currently has 786 employees.
What are the support and resistance levels for BURNING ROCK BIOTECH LTD-ADR (BNR) stock?
BURNING ROCK BIOTECH LTD-ADR (BNR) has a support level at 7.12 and a resistance level at 7.32. Check the full technical report for a detailed analysis of BNR support and resistance levels.
Is BURNING ROCK BIOTECH LTD-ADR (BNR) expected to grow?
The Revenue of BURNING ROCK BIOTECH LTD-ADR (BNR) is expected to grow by 20.21% in the next year. Check the estimates tab for more information on the BNR EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy BURNING ROCK BIOTECH LTD-ADR (BNR) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of BNR, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of BNR, evaluating the profitability, health, valuation and growth aspects
- BURNING ROCK BIOTECH LTD-ADR (BNR) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- BURNING ROCK BIOTECH LTD-ADR (BNR) Sales and EPS estimates to see what analysts future expectations are.
- BURNING ROCK BIOTECH LTD-ADR (BNR) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- BURNING ROCK BIOTECH LTD-ADR (BNR) Insider and Institutional Ownership to learn about the owners and their transactions.
- BURNING ROCK BIOTECH LTD-ADR (BNR) Stock Chart to make your own analysis
- BURNING ROCK BIOTECH LTD-ADR (BNR) Latest news and press-releases to stay up to date.
Does BURNING ROCK BIOTECH LTD-ADR (BNR) stock pay dividends?
BNR does not pay a dividend.
What is the Price/Earnings (PE) ratio of BURNING ROCK BIOTECH LTD-ADR (BNR)?
BURNING ROCK BIOTECH LTD-ADR (BNR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-25.56).
What is the Short Interest ratio of BURNING ROCK BIOTECH LTD-ADR (BNR) stock?
The outstanding short interest for BURNING ROCK BIOTECH LTD-ADR (BNR) is 0.84% of its float. Check the ownership tab for more information on the BNR short interest.
BNR Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to BNR. When comparing the yearly performance of all stocks, BNR is one of the better performing stocks in the market, outperforming 71.99% of all stocks.
BNR Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to BNR. While BNR seems to be doing ok healthwise, there are quite some concerns on its profitability.
BNR Financial Highlights
Over the last trailing twelve months BNR reported a non-GAAP Earnings per Share(EPS) of -25.56. The EPS increased by 73.34% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -43.41% | ||
| ROE | -65.96% | ||
| Debt/Equity | 0 |
BNR Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 80% to BNR. The Buy consensus is the average rating of analysts ratings from 5 analysts.
For the next year, analysts expect an EPS growth of 95.52% and a revenue growth 20.21% for BNR